drugset / Trial / NCT00057005
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
Phase 1
Completed
6 enrolled
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine · collabThe Methodist Hospital Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
Participants in this study have a hematologic malignancy which is a disorder in the bone marrow that affects the body's ability to create blood. Participants might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The participants donor is a family member. Stem cells are cells in the bone marrow and blood that can form a whole new blood system.
Timeline
- Start
- 2003-02
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD45 | Protein / enzyme biologic | 400 ug/kg | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 45 mg/kg | — |
| Background | Alemtuzumab | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | 45 mg/kg | — |
| Background | Cytarabine | Small molecule | 3000 mg/m2 | — |